Skip to main content
Premium Trial:

Request an Annual Quote

Nanosphere Commences Public Offering

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Nanosphere announced after the close of the market on Monday that it intends to offer 13.6 million shares of its common stock in a public offering.

The shares will be priced at $2.20 per share and Nanosphere expects proceeds from the offering to be about $27.9 million. If the underwriters exercise their over-allotment option in full, net proceeds will be about $32.1 million, it added.

Nanosphere said it intends to use net proceeds from the offering for general corporate purposes and working capital. It had previously raised $35.3 million in a public offering announced in October 2009.

Piper Jaffray is acting as the sole book-running agent manager on the current offering and Roth Capital Partners will act as co-manager.

The offering is expected to close on May 13 and is being made pursuant to a prospectus filed by the firm in September 2009.

In early morning trading on Tuesday on Nasdaq, shares of Nanosphere were down 26 percent to $2.16.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.